Verantos
Generates high-accuracy real-world evidence for clinical and regulatory use
Company facts
- Founded
- 2009
- Employees
- 60
- Headquarters
- United States
- CEO
- Dan Riskin
- Type
- Private
- Funding
- Grant · $1.5M · 2018
- Subsidiaries
- Verantos India
About
Verantos is a market leader in generating high-validity real-world evidence (RWE) for the life sciences sector. The company specializes in leveraging artificial intelligence (AI) and data science to transform real-world data (RWD) from sources like electronic health records (EHRs), medical claims, and registries into research-grade evidence. This high-validity RWE is crucial for various applications, including market access, medical affairs, regulatory submissions, and pharmacovigilance. Verantos's approach focuses on incorporating robust clinical narrative data and ensuring the accuracy, completeness, and traceability of the evidence generated. This allows life sciences organizations to gain deeper insights into disease progression, treatment effectiveness, and patient outcomes, ultimately accelerating clinical development and improving healthcare decisions. Founded in 2015 by Dr. Dan Riskin, a physician and expert in healthcare AI, Verantos was inspired by the potential of the 21st Century Cures Act to advance healthcare technology and the use of RWE. The company is headquartered in Menlo Park, California, in the heart of Silicon Valley. Verantos has developed a proprietary RWE platform that integrates heterogeneous data sources and employs AI-driven insights to produce evidence capable of supporting complex clinical studies and regulatory assertions. The company has collaborated with top-tier pharmaceutical and biotechnology firms, leading academic medical centers, and regulatory bodies such as the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the National Science Foundation (NSF). Verantos has been recognized for its contributions to the field, including being named 'BioInformatics Company of the Year' and consistently appearing on the Inc. 5000 list of fastest-growing private companies in America. The company's mission is to pioneer personalized medicine by setting the quality standard for real-world evidence and enabling a learning healthcare system where routine care data informs better patient outcomes.